Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized double-blind trial of an E. coli–produced 9-valent HPV vaccine in healthy women aged 18-45 years
CTR20201716Phase 3Active
- Sponsor
- Xiamen Wantai Canghai Biotechnology Co., Ltd.
- Start
- Sep 2020
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of recombinant human papillomavirus 9-valent vaccine in human papillomavirus infection, Cervical Cancer (CC), anogenital warts, sponsored by Xiamen Wantai Canghai Biotechnology Co., Ltd.. Started Sep 2020; status: active.
02
Drugs
recombinant human papillomavirus 9-valent vaccine
03
Conditions
human papillomavirus infectionCervical Cancer (CC)anogenital warts
Beyond the preview
Go deeper on CTR20201716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20201716.